Recent Quotes
My Watchlist
Indicators
REW 40 Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

48.17 +0.10 (+0.22%)
Streaming Delayed Price Updated: 2:05 PM EDT, Jun 29, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 5,216,433
Open 47.72
Bid (Size) 48.17 (500)
Ask (Size) 48.18 (1,300)
Prev. Close 48.07
Today's Range 47.61 - 48.39
52wk Range 35.12 - 71.80
Shares Outstanding N/A
Dividend Yield 5.29%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
2 Top Growth Stocks to Buy Right Now Without Hesitation ↗
These stocks are no-brainer buys. 
Via The Motley Fool
Topics Economy
News headline image
Will SpaceX Stock Double Anytime Soon? No -- but These 3 Stocks Could ↗
These stocks are better bets to skyrocket than the much-hyped rocket stock. 
Via The Motley Fool

Performance

YTD
-8.0%
-8.0%
1 Month
+5.7%
+5.7%
3 Month
+36.5%
+36.5%
6 Month
-6.4%
-6.4%
1 Year
-30.2%
-30.2%

More News

Read More
News headline image
Opinion: Pfizer Is a Fantastic Dividend Stock for Income Investors to Buy Right Now ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Better Buy in the Obesity Drug Race: Novo Nordisk or Eli Lilly? ↗
Via The Motley Fool
News headline image
An Analyst Just Declared Eli Lilly the "Clear Winner" of an American Diabetes Association Conference Focused on Weight-Loss Drugs. Novo's Chief Scientist Disagrees. Who's Right? ↗
Via The Motley Fool
News headline image
The Artificial Intelligence Opportunity Beyond Big Tech: 3 Healthcare Stocks to Watch ↗
Via The Motley Fool
Topics Artificial Intelligence
News headline image
2 Underrated Weight Loss Stocks to Buy and Hold ↗
Via The Motley Fool
News headline image
Why This Mid-Cap Biotech Could Be the Dark-Horse Threat to Eli Lilly and Novo Nordisk ↗
Via The Motley Fool
News headline image
Novo Nordisk's Wegovy Pill Just Hit 3 Million Prescriptions. Is Wall Street Missing Something With This Beaten-Down Stock? ↗
Via The Motley Fool
News headline image
3 Non-Pharma Firms That Could Benefit From the GLP-1 Trend ↗
Via MarketBeat
Topics ETFs
News headline image
Eli Lilly vs. Novo Nordisk: Better Obesity Drug Stock? ↗
Via The Motley Fool
News headline image
3 Under-the-Radar Stocks to Buy and Hold for a Decade ↗
Via The Motley Fool
News headline image
3 Reasons to Buy Eli Lilly Stock Like There's No Tomorrow ↗
Via The Motley Fool
News headline image
Pfizer's New Weight-Loss Data Just Gave Eli Lilly and Novo Nordisk Investors Something to Worry About ↗
Via The Motley Fool
News headline image
Is Viking Therapeutics Stock Going to $100? ↗
Via The Motley Fool
News headline image
Why Pfizer Stock Popped Today ↗
Via The Motley Fool
News headline image
80% of Wegovy Pill Users Never Took a Weight Loss Drug Before. Does This Number Change the Entire Novo Nordisk Bear Case? ↗
Via The Motley Fool
News headline image
Novo's Wegovy Pill Isn't Just Beating Expectations -- It's Obliterating Them. Is the Beaten-Down Stock a Buy Now? ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
CVS Health Just Announced Fantastic News to Eli Lilly Stock Investors ↗
Via The Motley Fool
News headline image
Eli Lilly Sees More Dealmaking Ahead as Management Looks To Leverage Its GLP-1 Success ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Forget Zepbound: Eli Lilly's Next Billion-Dollar Weight-Loss Drug May Be Even Better ↗
Via The Motley Fool
News headline image
Here's What I Think Is Really Going on With Novo Nordisk Stock ↗
Via The Motley Fool
News headline image
Bull vs. Bear: The Quick Take on Viking Therapeutics Stock ↗
Via The Motley Fool
News headline image
Eli Lilly Wins Back CVS Health, Reverting Novo's Advantage ↗
Via MarketBeat
News headline image
Viking Therapeutics' Q3 Catalyst That Could Turn Eli Lilly's and Novo Nordisk's Daily Weight Loss Pill Strategy Upside Down ↗
Via The Motley Fool

Frequently Asked Questions

Is Novo Nordisk A/S Common Stock publicly traded?
Yes, Novo Nordisk A/S Common Stock is publicly traded.
What exchange does Novo Nordisk A/S Common Stock trade on?
Novo Nordisk A/S Common Stock trades on the New York Stock Exchange
What is the ticker symbol for Novo Nordisk A/S Common Stock?
The ticker symbol for Novo Nordisk A/S Common Stock is NVO on the New York Stock Exchange
What is the current price of Novo Nordisk A/S Common Stock?
The current price of Novo Nordisk A/S Common Stock is 48.17
When was Novo Nordisk A/S Common Stock last traded?
The last trade of Novo Nordisk A/S Common Stock was at 06/29/26 02:05 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.